CYP2C19 GENE POLYMORPHISM AND ITS ASSOCIATION WITH THE CLINICAL EFFECT OF ESCITALOPRAM IN UYGHUR PATIENTS WITH DEPRESSION
Objective To investigate the distribution of CYP2C19 gene polymorphisms in Uyghur patients with depression and its association with the clinical effect of escitalopram.Methods A total of 36 Uyghur patients with depression were treated with 10-20 mg/d escitalopram for 4 weeks.The Hamilton Depression Scale (HAMD) was used to evaluate clinical outcome at weeks 2 and 4 of treatment,and the Treatment Emergent Symptom Scale (TESS) was used to assess adverse drug reactions.Gene microarray was used to evaluate CYP2C19 gene polymorphisms,and according to the presence or absence of mutant allele,the patients were divided into wild-type group and mutant group.Results Of all 36 Uyghur patients with depression,94.45 ％ were extensive metabolizers and 5.56％ were poor metabolizers.There was a significant difference in response rate after 2 weeks of escitalopram treatment between the wild type group and the mutant group (22.73％ vs 64.29％,x2 =6.218,P＜0.05).After 4 weeks of treatment,there was no significant difference in response rate between the two groups (P＞0.05).Atthe end of week 2,the mutant group had a significantly higher TESS score than the wild-type group (t-2.594,P＜0.05);at the end of week 4,there was no significant difference in TESS score between the two groups (P＞0.05).Conclusion CYP2C19 gene polymor phisms may be associated with the clinical effect and adverse effect of escitalopram.
depressive disorderCYP2C19polymorphism, single nucleotideescitalopramtreatment outcomeanalysis of variance
NETL
NSTL
万方数据
维普
